Polypharmacy Side Effect Prediction with Graph Convolutional Neural Network Based on Heterogeneous Structural and Biological Data

Total Page:16

File Type:pdf, Size:1020Kb

Polypharmacy Side Effect Prediction with Graph Convolutional Neural Network Based on Heterogeneous Structural and Biological Data DEGREE PROJECT IN MATHEMATICS, SECOND CYCLE, 30 CREDITS STOCKHOLM, SWEDEN 2020 Polypharmacy Side Effect Prediction with Graph Convolutional Neural Network based on Heterogeneous Structural and Biological Data JUAN SEBASTIAN DIAZ BOADA KTH ROYAL INSTITUTE OF TECHNOLOGY SCHOOL OF ENGINEERING SCIENCES Polypharmacy Side Effect Prediction with Graph Convolutional Neural Network based on Heterogeneous Structural and Biological Data JUAN SEBASTIAN DIAZ BOADA Degree Projects in Scientific Computing (30 ECTS credits) Master’s Programme in Computer Simulations for Science and Engineering KTH Royal Institute of Technology year 2020 Supervisor at KI Algorithmic Dynamics Lab, Center for Molecular Medicine: Narsis A. Kiani Supervisor at KTH: Michael Hanke Examiner at KTH: Michael Hanke TRITA-SCI-GRU 2020:390 MAT-E 2020:097 Royal Institute of Technology School of Engineering Sciences KTH SCI SE-100 44 Stockholm, Sweden URL: www.kth.se/sci iii Acknowledgements This thesis and its experiments were performed in the Algorithmic Dynamics Lab of the Center for Molecular Medicine. Special thanks to Amir Amanzadi for creating the affinity score dataset, Jesper Tegnér for his comments analyz- ing results and Linus Johnson for his help with the Swedish translation. v Abstract The prediction of polypharmacy side effects is crucial to reduce the mortal- ity and morbidity of patients suffering from complex diseases. However, its experimental prediction is unfeasible due to the many possible drug combi- nations, leaving in silico tools as the most promising way of addressing this problem. This thesis improves the performance and robustness of a state-of- the-art graph convolutional network designed to predict polypharmacy side effects, by feeding it with complexity properties of the drug-protein network. The modifications also involve the creation of a direct pipeline to reproduce the results and test it with different datasets. vi Sammanfattning Förutsägning av biverkningar från polyfarmaci med grafiska faltnings- neuronnät baserat på heterogen strukturell och biologisk data För att minska dödligheten och sjukligheten hos patienter som lider av kom- plexa sjukdomar är det avgörande att kunna förutsäga biverkningar från poly- farmaci. Att experimentellt förutsäga biverkningarna är dock ogenomförbart på grund av det stora antalet möjliga läkemedelskombinationer, vilket läm- nar in silico-verktyg som det mest lovande sättet att lösa detta problem. Detta arbete förbättrar prestandan och robustheten av ett av det senaste grafiska falt- ningsnätverken som är utformat för att förutsäga biverkningar från polyfarma- ci, genom att mata det med läkemedel-protein-nätverkets komplexitetsegen- skaper. Ändringarna involverar också skapandet av en direkt pipeline för att återge resultaten och testa den med olika dataset. Contents Acknowledgements iii 1 Introduction 1 1.1 Statement of the problem . .1 1.2 Thesis Objective . .2 1.3 Outline of Thesis . .3 2 Theoretical Framework 4 2.1 Supervised Learning . .4 2.1.1 Linear Models . .6 2.1.2 Tree-based Methods . .7 2.1.3 Support Vector Machines . .8 2.1.4 Bayesian Methods . .8 2.2 Deep Learning . .9 2.2.1 Feedforward Neural Networks . 10 2.2.2 Training Feed-forward Neural Networks . 14 2.2.3 Convolutional Neural Networks . 24 2.2.4 Graph Convolutional Networks . 27 2.3 Algorithmic Complexity . 32 3 Related Work and State of the Art 36 3.1 Traditional synergy calculations . 37 3.2 General Methods . 39 3.3 Trainable Methods . 40 3.3.1 Linear Regression Methods . 40 3.3.2 Tree-based methods . 41 3.3.3 Other Machine Learning Approaches . 41 3.4 Deep Learning Methods . 42 3.4.1 Standard Deep Learning Methods . 42 vii viii CONTENTS 3.4.2 Decagon . 43 3.4.3 Decagon-based methods . 48 4 Materials and Methods 49 4.1 Datasets . 49 4.2 Original Implementation of Decagon . 52 4.2.1 Data structure organisation . 53 4.3 Contributions and improvements to Decagon . 59 4.3.1 Data Treatment and Preparation . 60 4.3.2 Implementation of Algorithmic Complexity Features . 64 4.3.3 Containers and GPU Configuration . 70 4.3.4 Minibatch sampling and the data leakage problem . 71 4.3.5 Incorporation of edge features . 73 4.3.6 Other improvements . 73 4.3.7 Overall Pipeline . 74 5 Results and Discussion 76 5.1 First experiments: Feature selection . 76 5.2 Node features as possible method stabilisers . 79 5.3 Experiments with side effects with the lowest performance . 83 5.4 Extension to experiments with a full graph . 87 6 Conclusions 97 Bibliography 102 A Additional figures 111 Acronyms and Abbreviations ADR adverse drug reaction. 1, 2, 4, 36, 42 AI Artificial intelligence. 4 ANN artificial neural network. 10, 12–14, 19, 21, 22, 25, 26 AP algorithmic probability. 33 AP@K average precision at k. 24 API application programming interface. 97 ATC Anatomical Therapeutic Chemical. 36, 40–42 AUPRC area under the precision-recall curve. 23, 24, 59, 76, 78, 79, 81, 86, 88–94, 112, 113 AUROC area under the receiving operating characteristics curve. 24, 59, 76, 79, 89 BDM Block decomposition method or KC features calculated with the block decomposition method. 34, 35, 64, 67–69, 71, 74–77, 79–81, 83, 85, 87–90, 98, 100 CNN convolutional neural network. 25–29 CPU central processing unit. 20, 71, 76 CSR compressed sparse row. 56, 63 CTM coding theorem method. 33, 34, 65, 66 DDI drug-drug interaction. 3, 41–44, 47, 48, 53, 54, 60, 62–64, 69, 70, 99 DL Deep learning. 9, 10, 24, 25, 27–29, 41–43, 45 ix x Acronyms and Abbreviations DSE Single drug side effects. 50, 60, 63, 74, 76, 77, 79–81, 84, 85, 87, 89, 90, 93–95, 99 DTI drug-target interaction. 3, 41, 43, 44, 47, 50, 52–54, 56, 60–64, 69, 73, 78, 99 EMI Edge Minibatch Iterator. 55, 56, 59, 72–74, 80, 81, 83, 88, 89, 100 FN false negatives. 22 FP false positives. 22 GCN graph convolutional network. 2, 28, 29, 31, 52, 57, 58, 60, 61, 64, 73, 81, 97–99 GPU graphic processing unit. 20, 69–71, 74–76, 87, 88, 95, 97, 100 KC Kolmogorov complexity. 32–34 MedDRA Medical Dictionary for Regulatory Activities. 50, 51 ML Machine learning. 4–6, 9, 10, 15, 21, 34, 36, 37, 40 MSE mean squared error. 15 PPI protein-protein interaction. 3, 40, 43, 44, 47, 50, 53, 54, 56, 61–64, 69, 78 ReLU rectified linear unit. 19, 20, 25, 31, 57, 73, 87 RF Random forests. 7, 41 SGD stochastic gradient descent. 17, 18, 21, 35 SVMs Support vector machines. 8, 41, 42 TN true negatives. 24 TP true positives. 22 UTM universal Turing machine. 32–34 w2 Simulations including DSE and BDM features. 81, 87, 89, 90, 93–95 Chapter 1 Introduction 1.1 Statement of the problem In many complex diseases, single-drug therapies fall short in helping recover- ing patients. This lower performance occurs because complex diseases such as cancer or AIDS, involve processes controlled by multiple biochemical mecha- nisms, which give redundancy to their functioning [1–3]. Usually, from all the targets that a drug may have, only a few of them are known, which give insight to which diseases they can treat. Single drug therapies target only a limited number of pathways in the pathogenesis of a disease, which sometimes leads to an incomplete treatment and, therefore, perpetuates the disease. As a result, new procedures have shifted towards multi-drug therapies, which have proven to boost the efficacy of cancer, AIDS and fungal infection treat- ments over single drug therapies [4–7]. The potentiated polypharmacy effect comes from drug synergy, occurring when multiple drugs undertake the same disease by simultaneously targeting different pathophysiological pathways [1, 5]. Due to this effect, the single-drug doses can be reduced [8, 9], which con- tributes to reducing the individual toxicity of the drugs [2, 4–6, 10], and even reduce the drug resistance of the disease [6, 8, 11, 12]. Nevertheless, polypharmacy is associated with a much higher risk of adverse drug reactions (ADRs) due to drug-drug interactions [1, 4, 13]. Single drugs may modulate the activity of various untracked proteins in what is known as off-target interactions, which are challenging to trace [1, 14]. Multiple inter- actions of this kind could give rise to unexpected polypharmacy ADRs. These interactions usually go unnoticed in clinical trials, due to the limited time spent 1 2 CHAPTER 1. INTRODUCTION in testing drug combinations [15] and being, most of the times, discovered once the drug is already in the market [14]. As the mechanistic understand- ing of drug-drug interactions is low, it is difficult to predict these side effects [2]. Furthermore, polypharmacy therapies are getting more common [16], be- coming a growing problem and being the cause of a significant fraction of the hospitalisation of patients due to unexpected ADRs [17, 18]. Until recently, the prognostication of polypharmacy ADRs was mainly based on clinical experience [2, 4] and medical expertise [8]. Some classical quan- titative methods to predict the effect of drug combinations, such as the Loewe model (see section 3.1), were also used but failed to fully explain non-linear interactions such as synergy [4, 5, 19]. Clinical experiments can give a solu- tion for a few combinations, but they are time-consuming and expensive [2, 5]. In vitro approaches like high-throughput screening can lead to cheaper proce- dures, but the vast combinatorial space of drugs makes it unfeasible to test all drug combinations [2, 4]. Therefore, it is necessary to have some development in the preclinical trials to make the procedure more sustainable and efficient. In silico approaches come handy to solve these problems. These are computational methods to simu- late the effect of drug combinations rapidly and with low resource investment.
Recommended publications
  • 2019 Ministerial Declaration
    COMMISSION ON NARCOTIC DRUGS VIENNA IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Commission on Narcotic Drugs IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS Vienna, 2019 © United Nations, July 2019. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Contents 1. Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem ...............................1 2. Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem” ..................................................9 3. Joint Ministerial Statement of the 2014 High-Level Review by the Commission on Narcotic Drugs of the Implementation by Member States of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem ...............................35 4.
    [Show full text]
  • Synthetic Drugs: Overview and Issues for Congress
    Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700 www.crs.gov R42066 Synthetic Drugs: Overview and Issues for Congress Summary Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. From 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as “K2” and “Spice”) and stimulants (such as “bath salts”) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013.
    [Show full text]
  • Exposures Associated with Clandestine Methamphetamine Drug Laboratories in Australia
    Rev Environ Health 2016; 31(3): 329–352 Jackie Wright*, John Edwards and Stewart Walker Exposures associated with clandestine methamphetamine drug laboratories in Australia DOI 10.1515/reveh-2016-0017 Received April 20, 2016; accepted June 7, 2016; previously published Introduction online July 18, 2016 Illicit drugs such as amphetamine-type stimulants (ATS) Abstract: The clandestine manufacture of methamphet- (1) are manufactured in Australia within clandestine amine in residential homes may represent significant laboratories that range from crude, makeshift operations hazards and exposures not only to those involved in the using simple processes to sophisticated operations. These manufacture of the drugs but also to others living in the laboratories use a range of chemical precursors to manu- home (including children), neighbours and first respond- facture or “cook” ATS that include methylamphetamine, ers to the premises. These hazards are associated with more commonly referred to as methamphetamine (“ice”) the nature and improper storage and use of precursor and 3,4-methylenedioxymethamphetamine (MDMA or chemicals, intermediate chemicals and wastes, gases and “ecstasy”). In Australia the primary ATS manufactured methamphetamine residues generated during manufac- in clandestine drug laboratories is methamphetamine ture and the drugs themselves. Many of these compounds (2), which is the primary focus of this review. Clandes- are persistent and result in exposures inside a home not tine laboratories are commonly located within residential only during manufacture but after the laboratory has been homes, units, hotel rooms, backyard sheds and cars, with seized or removed. Hence new occupants of buildings for- increasing numbers detected in Australia each year (744 merly used to manufacture methamphetamine may be laboratories detected in 2013–2014) (2).
    [Show full text]
  • Nitrosamines EMEA-H-A5(3)-1490
    25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • The Clinical Toxicology of Gamma-Hydroxybutyrate, Gamma-Butyrolactone and 1,4-Butanediol
    Clinical Toxicology (2012), 50: 458–470 Copyright © 2012 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2012.702218 REVIEW ARTICLE The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol LEO J SCHEP 1 , KAI KNUDSEN 2 , ROBIN J SLAUGHTER 1 , J ALLISTER VALE 3 , and BRUNO MÉGARBANE 4 1 National Poisons Centre, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand 2 Department of Anesthesia and Intensive Care Medicine, Surgical Sciences, Blå Stråket 5, Sahlgrenska University Hospital, Gothenburg, Sweden 3 National Poisons Information Service (Birmingham Unit) and West Midlands Poisons Unit, City Hospital, Birmingham, UK; School of Biosciences and College of Medical and Dental Sciences, University of Birmingham, Birmingham,UK 4 Hôpital Lariboisière, Réanimation Médicale et Toxicologique, INSERM U705, Université Paris-Diderot, Paris, France Introduction. Gamma-hydroxybutyrate (GHB) and its precursors, gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), are drugs of abuse which act primarily as central nervous system (CNS) depressants. In recent years, the rising recreational use of these drugs has led to an increasing burden upon health care providers. Understanding their toxicity is therefore essential for the successful management of intoxicated patients. We review the epidemiology, mechanisms of toxicity, toxicokinetics, clinical features, diagnosis, and management of poisoning due to GHB and its analogs and discuss the features and management of GHB withdrawal. Methods. OVID MEDLINE and ISI Web of Science databases were searched using the terms “ GHB, ” “ gamma-hydroxybutyrate, ” “ gamma-hydroxybutyric acid, ” “ 4-hydroxybutanoic acid, ” “ sodium oxybate, ” “ gamma-butyrolactone, ” “ GBL, ” “ 1,4-butanediol, ” and “ 1,4-BD ” alone and in combination with the keywords “ pharmacokinetics, ” “ kinetics, ” “ poisoning, ” “ poison, ” “ toxicity, ” “ ingestion, ” “ adverse effects, ” “ overdose, ” and “ intoxication.
    [Show full text]
  • Page 498 TITLE 21—FOOD AND
    § 695 TITLE 21—FOOD AND DRUGS Page 498 pealed the permanent appropriation under the title Sec. ‘‘Meat inspection, Bureau of Animal Industry (fiscal 822. Persons required to register. year) (3–114)’’ effective July 1, 1935, provided that such 823. Registration requirements. portions of any Acts as make permanent appropriations 824. Denial, revocation, or suspension of registra- to be expended under such account are amended so as tion. to authorize, in lieu thereof, annual appropriations 825. Labeling and packaging. from the general fund of the Treasury in identical 826. Production quotas for controlled substances. terms and in such amounts as now provided by the laws 827. Records and reports of registrants. providing such permanent appropriations, and author- 828. Order forms. ized, in addition thereto, the appropriation of ‘‘such 829. Prescriptions. other sums as may be necessary in the enforcement of 830. Regulation of listed chemicals and certain the meat inspection laws.’’ In the original, the par- machines. enthetical ‘‘(U.S.C., title 21, secs. 71 to 96, inclusive)’’ 831. Additional requirements relating to online followed the phrase ‘‘meat inspection laws’’. The ‘‘meat pharmacies and telemedicine. inspection laws’’ are classified generally to this chap- ter. PART D—OFFENSES AND PENALTIES Section was not enacted as part of the Federal Meat 841. Prohibited acts A. Inspection Act which is classified to subchapters I to 842. Prohibited acts B. IV–A of this chapter. 843. Prohibited acts C. Section was formerly classified to section 95 of this 844. Penalties for simple possession. title. 844a. Civil penalty for possession of small amounts § 695. Payment of cost of meat-inspection service; of certain controlled substances.
    [Show full text]
  • Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/08/03/jpet.116.234781.DC1 1521-0103/359/1/134–141$25.00 http://dx.doi.org/10.1124/jpet.116.234781 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:134–141, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function s Jahnabi Roy, Reheman Adili, Richard Kulmacz, Michael Holinstat, and Aditi Das Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), University of Michigan Medical School, Ann Arbor, Michigan; and Department of Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, Texas (R.K.) Received April 27, 2016; accepted August 1, 2016 Downloaded from ABSTRACT The inhibition of platelet aggregation is key to preventing particular, the aspirin-DHA anhydride displayed similar effective- conditions such as myocardial infarction and ischemic stroke. ness to aspirin. Platelet aggregation studies conducted in the Aspirin is the most widely used drug to inhibit platelet aggre- presence of various platelet agonists indicated that the aspirin-lipid gation. Aspirin absorption can be improved further to increase conjugates act through inhibition of the cyclooxygenase (COX)– jpet.aspetjournals.org its permeability across biologic membranes via esterification thromboxane synthase (TXAS) pathway.
    [Show full text]
  • Polysubstance Use Disorder
    Driving-Under-the-Influence (DUI) Medication Assisted Treatment (MAT) Polysubstance Integration/Outreach Pilot Project Use Disorder The DUI MAT Integration/Outreach Pilot What is Polysubstance Abuse? Project targets the development and Poly drug use refers to combined drug intoxication to achieve a particular effect. implementation of a recognition and in- In many cases one drug is used as a base, or primary drug, with additional drugs to tervention pilot program for Opioid Use lessen or compensate for the side effects of the primary drug and make the expe- Disorder (OUD) and Polysubstance Use rience more enjoyable with drug synergy effects, or to supplement for the primary Disorder (SUD) to benefit DUI program drug when supply is low. participants. This can include any two substances that create a dependency or negative impact in your life! Examples include alcohol and marijuana, alcohol and prescription DUI MAT services include education, medication, methamphetamine and alcohol. Any two substances used together pre-screens and 2nd level screenings, can result in a Polysubstance use disorder. Although Medication-Assisted Treat- treatment referrals, and counseling sup- ment (MAT) may not be appropriate to treat this issue, there are multiple treatment port. options available. DUI MAT is a voluntary program and will Is the DUI MAT Program Right for You? not impact your DUI program or any le- gal proceedings. DUI MAT is for anyone currently enrolled in a participating DUI Program who may have a substance abuse problem. While the project was developed to address the opioid crisis, you do not need to be exclusively dependent on opioids to participate in the DUI MAT program.
    [Show full text]
  • Diagonal Method to Measure Synergy Among Any Number of Drugs
    Journal of Visualized Experiments www.jove.com Video Article Diagonal Method to Measure Synergy Among Any Number of Drugs Melike Cokol-Cakmak1, Feray Bakan2, Selim Cetiner1, Murat Cokol1,2,3 1 Faculty of Engineering and Natural Sciences, Sabanci University 2 Nanotechnology Research and Application Center, Sabanci University 3 Laboratory of Systems Pharmacology, Harvard Medical School Correspondence to: Murat Cokol at [email protected] URL: https://www.jove.com/video/57713 DOI: doi:10.3791/57713 Keywords: Biology, Issue 136, Drug interactions, checkerboard assay, drug synergy, drug combinations, Loewe additivity model, high-order drug interactions Date Published: 6/21/2018 Citation: Cokol-Cakmak, M., Bakan, F., Cetiner, S., Cokol, M. Diagonal Method to Measure Synergy Among Any Number of Drugs. J. Vis. Exp. (136), e57713, doi:10.3791/57713 (2018). Abstract A synergistic drug combination has a higher efficacy compared to the effects of individual drugs. Checkerboard assays, where drugs are combined in many doses, allow sensitive measurement of drug interactions. However, these assays are costly and do not scale well for measuring interaction among many drugs. Several recent studies have reported drug interaction measurements using a diagonal sampling of the traditional checkerboard assay. This alternative methodology greatly decreases the cost of drug interaction experiments and allows interaction measurement for combinations with many drugs. Here, we describe a protocol to measure the three pairwise interactions and one three-way interaction among three antibiotics in duplicate, in five days, using only three 96-well microplates and standard laboratory equipment. We present representative results showing that the three-antibiotic combination of Levofloxacin + Nalidixic Acid + Penicillin G is synergistic.
    [Show full text]
  • Drug Combinations: Mathematical Modeling and Networking Methods
    pharmaceutics Review Drug Combinations: Mathematical Modeling and Networking Methods Vahideh Vakil † and Wade Trappe *,† Wireless Information Network Laboratory (WINLAB), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-848-932-0909 † Current address: Technology Centre of New Jersey, 671 Route 1 South, North Brunswick, NJ 08902-3390, USA. Received: 12 February 2019; Accepted: 27 April 2019; Published: 2 May 2019 Abstract: Treatments consisting of mixtures of pharmacological agents have been shown to have superior effects to treatments involving single compounds. Given the vast amount of possible combinations involving multiple drugs and the restrictions in time and resources required to test all such combinations in vitro, mathematical methods are essential to model the interactive behavior of the drug mixture and the target, ultimately allowing one to better predict the outcome of the combination. In this review, we investigate various mathematical methods that model combination therapies. This survey includes the methods that focus on predicting the outcome of drug combinations with respect to synergism and antagonism, as well as the methods that explore the dynamics of combination therapy and its role in combating drug resistance. This comprehensive investigation of the mathematical methods includes models that employ pharmacodynamics equations, those that rely on signaling and how the underlying chemical networks are affected by the topological structure of the target proteins, and models that are based on stochastic models for evolutionary dynamics. Additionally, this article reviews computational methods including mathematical algorithms, machine learning, and search algorithms that can identify promising combinations of drug compounds.
    [Show full text]
  • Drug-Facilitated Sexual Assault in the U.S
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants.
    [Show full text]